Thermo Fisher Sells Microbiology Business to Astorg for $1 Billion

Thermo Fisher Scientific has agreed to sell its microbiology business unit to French private equity firm Astorg for approximately $1 billion. The deal was announced as part of Thermo Fisher's strategy to streamline its portfolio and focus on core operations. The sale covers the unit operating in areas such as clinical microbiology, food safety, and environmental testing. This unit generated approximately $500 million in revenue in 2023. Astorg aims to strengthen its presence in the healthcare and life sciences sector through this acquisition. The transaction is expected to close in the first quarter of 2025. Thermo Fisher plans to use the proceeds from the deal to reduce debt and enhance shareholder value. Following the sale, the company will focus on areas with higher growth potential. This transaction stands out as one of the largest divestitures Thermo Fisher has made in recent years. The company had previously optimized its portfolio through similar strategic moves. Astorg, meanwhile, is expanding its investment portfolio in the healthcare sector with this acquisition. This is not investment advice.